Australia
Russell Kennedy's Gina Tresidder on juggling matters, delivering hard truths, and why IP ownership is rarely as simple as people think
As competing firms come under common ownership, clients may care less about formal conflicts and more about how openly firms discuss them
IPH’s strategy of integrating acquired businesses into its larger premium brands, may offer an early signal of how externally funded IP firms will pursue scale, efficiency and market strength
Peter O’Sullivan, a professional services executive, says he is looking forward to helping Pearce IP become the leading life sciences firm in Australia and New Zealand
Sponsored
Sponsored
-
Sponsored by Griffith HackSoftware and patents have always had a difficult relationship. Around the world, different rules in different jurisdictions create uncertainty for innovators wanting to know if their key innovations can be secured or whether the market is a free-for-all against competitors. -
Sponsored by Griffith HackTrack and trace smartphone applications used in the fight against COVID-19 are representative of a relatively new industry falling between the healthcare, IT, medical devices and pharmaceutical sectors.
-
Sponsored by Griffith HackMānuka is the Māori name for the Leptospermum scoparium, a species of flowering plant in the myrtle family, Myrtaceae. Mānuka nectar is renowned for producing 'liquid gold', a pure honey possessing unique medicinal and antibacterial qualities.
-
Sponsored by Griffith HackIn early 2019, IP Australia initiated a comprehensive research phase exploring Australia’s design ecosystem, including voices from the industry, design forums, economic analysis and business surveys. Following this 12-month exercise, the regulator has proposed the following changes:
-
Sponsored by Griffith HackDespite being a market of only 26 million people, Australia possesses a world-class healthcare system and well regarded scientific community. This is most recently demonstrated through the participation of Australian scientists in the race to successfully manufacture a COVID-19 vaccine, and by the low infection death rates from the current pandemic in Australia.
